AR053799A1 - Composiciones que contienen policonasol y teaflavina y sus usos farmaceuticos - Google Patents
Composiciones que contienen policonasol y teaflavina y sus usos farmaceuticosInfo
- Publication number
- AR053799A1 AR053799A1 ARP060100201A ARP060100201A AR053799A1 AR 053799 A1 AR053799 A1 AR 053799A1 AR P060100201 A ARP060100201 A AR P060100201A AR P060100201 A ARP060100201 A AR P060100201A AR 053799 A1 AR053799 A1 AR 053799A1
- Authority
- AR
- Argentina
- Prior art keywords
- teaflavin
- policosanol
- diseases
- drug
- support layer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
Composicion que contiene policosanol y teaflavina y que puede usarse para tratar y/o reducir enfermedades hipercolesterolémicas, colesterol total, colesterol de LDL, enfermedad cardíaca coronaria (ataques al corazon y accidentes cerebrovasculares), inflamacion, trombosis venosa profunda, enfermedades inmunorregulatorias, enfermedades cardiovasculares y/o trastornos neurogenerativos en humanos y animales. El método comprende administrar policosanol y teaflavina, que juntos disminuyen efectivamente los niveles séricos de colesterol. Generalmente, la composicion administrada incluye una mezcla de aproximadamente 0,1-10:1 partes en peso de policosanol respecto de teaflavina. Reivindicacion 24: Un equipo que comprende un primer contenedor que comprende una formulacion de liberacion controlada de policosanol y teaflavina en una cantidad efectiva para tratar o reducir y/o prevenir enfermedades hipercolesterolémicas, colesterol total, colesterol de LDL, enfermedad cardíaca coronaria (ataques al corazon y accidentes cerebrovasculares), inflamacion, enfermedades inmunorregulatorias, enfermedades cardiovasculares y/o trastornos neurodegenerativos. Reivindicacion 25: El equipo de la reivindicacion 24, que además comprende una aguja para puncion o un catéter. Reivindicacion 26: Un artículo de fabricacion que comprende: un cuerpo de endoprotesis vascular (stent) que comprende una superficie; y un recubrimiento que comprende por lo menos una capa dispuesta sobre por lo menos una parte del cuerpo de la endoprotesis vascular, en donde dicha capa comprende una película de polímero que tiene policosanol y teaflavina dispersos en ella. Reivindicacion 36: Un sistema de administracion transdérmica para aplicar a la piel de un paciente, que comprende: a) una capa de soporte impermeable a la droga; b) una capa adhesiva; c) una membrana permeable a la droga, en donde la membrana se coloca en relacion a la capa de soporte de modo tal de formar por lo menos un reservorio para la droga entre la membrana y la capa de soporte; y d) una composicion que comprende policosanol y teaflavina contenida dentro del reservorio de droga en una concentracion suficiente para que el sistema de administracion transdérmica tenga una velocidad de entrada cuando se aplica a la piel suficiente para producir una concentracion plásmica en estado de equilibrio farmacéuticamente efectiva de policosanol y teaflavina en el paciente. Reivindicacion 38: Un implante subcutáneo que comprende policosanol y teaflavina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64554805P | 2005-01-20 | 2005-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053799A1 true AR053799A1 (es) | 2007-05-23 |
Family
ID=36284786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100201A AR053799A1 (es) | 2005-01-20 | 2006-01-19 | Composiciones que contienen policonasol y teaflavina y sus usos farmaceuticos |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR053799A1 (es) |
| PE (1) | PE20060862A1 (es) |
| TW (1) | TW200637536A (es) |
| WO (1) | WO2006078600A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156662A1 (en) * | 2006-04-26 | 2009-06-18 | Ito En, Ltd. | Fat Absorption Inhibitor |
| US9861590B2 (en) | 2010-10-19 | 2018-01-09 | Covidien Lp | Self-supporting films for delivery of therapeutic agents |
| WO2020218755A1 (ko) * | 2019-04-25 | 2020-10-29 | ㈜아모레퍼시픽 | 테아플라빈을 포함하는 지방세포 분화 촉진용 조성물 |
| KR102359446B1 (ko) * | 2019-04-25 | 2022-02-09 | (주)아모레퍼시픽 | 테아플라빈을 포함하는 지방세포 분화 촉진용 조성물 |
| CN112915077A (zh) * | 2021-02-18 | 2021-06-08 | 南昌大学附属口腔医院(江西省口腔医院) | 一种口腔酸蚀剂及其制备方法、应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7157493B2 (en) * | 2001-11-28 | 2007-01-02 | Nashai Biotech, Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof |
| US6565896B1 (en) * | 2002-07-03 | 2003-05-20 | Vitacost.Com, Inc. | Cholesterol treatment formulation |
| US20040097432A1 (en) * | 2002-11-04 | 2004-05-20 | Access Business Group International Llc. | Method of reducing cholesterol |
| US20040202732A1 (en) * | 2003-04-11 | 2004-10-14 | Brown William Stewart | Composition to promote weight loss |
-
2006
- 2006-01-13 WO PCT/US2006/001486 patent/WO2006078600A1/en active Application Filing
- 2006-01-18 PE PE2006000075A patent/PE20060862A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100201A patent/AR053799A1/es not_active Application Discontinuation
- 2006-01-19 TW TW095102065A patent/TW200637536A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20060862A1 (es) | 2006-10-13 |
| TW200637536A (en) | 2006-11-01 |
| WO2006078600A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tiwary et al. | Innovations in transdermal drug delivery: formulations and techniques | |
| DOP2017000239A (es) | Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia | |
| US20050226922A1 (en) | Apparatus and method for transdermal delivery of fentanyl-based agents | |
| AR046697A1 (es) | Metodo y sistema de administracion transdermica de agente asistido por frecuencia | |
| MX349176B (es) | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. | |
| NZ597307A (en) | Rejuvenating coronary artery by improving blood flow with the help of insertion of nano-balls (encapsulated nanoparticles) containing therapeutic agents by non implantable device for tissues and thereby providing in tissue release to address the required cell cycle | |
| ES2621915T3 (es) | Composiciones y métodos para la administración transdérmica de anfetamina | |
| AR046307A1 (es) | Metodo de pretratamiento y sistema para mejorar la administracion transdermica de drogas | |
| US20080311178A1 (en) | Gel composition and use thereof | |
| AR053799A1 (es) | Composiciones que contienen policonasol y teaflavina y sus usos farmaceuticos | |
| BRPI0411032A (pt) | composição adesiva hidrófila, artigo médico, método para a fabricação da composição adesiva, e, dispositivo de administração transdérmica | |
| WO2013078257A3 (en) | Implantable solid-liquig drug delivery apparatus, formulations, and methods of use | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| ES2410532T3 (es) | Adhesivo de acrilo útil en sistemas de administración transdérmica de fármacos | |
| JP6634623B2 (ja) | 溶解型マイクロニードル製剤 | |
| JP2017508749A5 (es) | ||
| DE19957234A1 (de) | Pharmazeutisches Pflaster enthaltend ätherische Öle | |
| AR122341A1 (es) | Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc) | |
| AU765429B2 (en) | Method of enhancing needleless transdermal powdered drug delivery | |
| John | Review on transdermal drug delivery system | |
| WO2008088536A3 (en) | Differential drug release from a medical device | |
| TWI354557B (en) | Transdermal steroid formulation | |
| ES2199954T3 (es) | Administracion transdermica de cetorolac. | |
| Deulkar et al. | A review on transdermal drug delivery system | |
| US20070196490A1 (en) | Method of enhancing needleless transdermal powered drug delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |